SCHEMBL26466965

SCHEMBL26466965

COCc1ccc(N)c(C(=O)OC)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.76
GAA P10253 6/20 0.76
KDM4E B2RXH2 5/20 0.76
HSD17B10 Q99714 3/20 0.76
MAPT P10636 2/20 0.76
HPGD P15428 2/20 0.76
ALOX15 P16050 1/20 0.76
TSHR P16473 1/20 0.76
CFTR P13569 3/20 0.51
GLA P06280 2/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
ATM Q13315 1/20 0.47
ABL1 P00519 1/20 0.46
CDC25B P30305 1/20 0.46
CASP6 P55212 1/20 0.46
RCE1 Q9Y256 1/20 0.46
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
CA12 O43570 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13162548 0.87 ALDH1A1 (0.60) ALDH1A1GAAKDM4EHSD17B10MAPT
SCHEMBL221403 0.86 ALDH1A1 (0.81) ALDH1A1GAAKDM4EHSD17B10MAPT
SCHEMBL1809277 0.86 ALDH1A1 (1.00) ALDH1A1GAAKDM4EHSD17B10MAPT
SCHEMBL30041521 0.86 ALDH1A1 (1.00) ALDH1A1GAAKDM4EHSD17B10MAPT
SCHEMBL13163983 0.86 ALDH1A1 (0.69) ALDH1A1GAAKDM4EHSD17B10MAPT
SCHEMBL14081421 0.85 ALDH1A1 (0.78) ALDH1A1GAAKDM4EHSD17B10MAPT
SCHEMBL29264027 0.85 ALDH1A1 (0.66) ALDH1A1GAAKDM4EHSD17B10MAPT
SCHEMBL25230816 0.82 ALDH1A1 (0.73) ALDH1A1GAAKDM4EHSD17B10MAPT
SCHEMBL7649762 0.82 ALDH1A1 (0.73) ALDH1A1GAAKDM4EHSD17B10MAPT
SCHEMBL534046 0.81 ALDH1A1 (0.68) ALDH1A1GAAKDM4EHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400562-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO, INC. 2024-12-05 US disclosed
CN-118339149-A Compounds and compositions for treating conditions associated with LPA receptor activity 罗特斯生物公司 2024-07-12 CN disclosed
WO-2023066359-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO, INC. (US) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400562-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LPAR1, LPAR2, LPAR6 ALDH1A1 1774/4885GAA 414/4885KDM4E 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.